| Description | LY2140023 has the potential for schizophrenia.LY2140023 is an orally active prodrug of LY404039. LY404039 is a selective metabotropic glutamate 2/3 receptor agonist. |
| In vivo | LY2140023 (orally;?3, 10, and 300 mg/kg;?once daily for 7 days) dose-dependent increases the levels of the dopamine metabolites dihydroxyphenylacetic acid and homovanillic acid (HVA)[1]. |
| Synonyms | LY2140023 |
| molecular weight | 366.41 |
| Molecular formula | C12H18N2O7S2 |
| CAS | 635318-55-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Lowe S, et al. Effects of a novel mGlu |
Pomaglumetad methionil anhydrous
CAS No.: 635318-55-7
LY2140023 has the potential for schizophrenia.LY2140023 is an orally active prodrug of LY404039. LY404039 is a selective
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.